Impax Settles With Daiichi, Genzyme Over Generic Welchol

Law360, New York (June 30, 2011, 12:27 PM EDT) -- Impax Laboratories Inc. said Thursday it had resolved patent litigation brought by Daiichi Sankyo Inc and Genzyme Corp. in Delaware over cholesterol drug Welchol, striking a deal that will allow Impax to launch a generic version in 2015.

As part of the settlement, Impax said it would be permitted to launch a generic Welchol tablet on March 2, 2015 — or earlier under certain circumstances. The settlement also allows for a release of generic Welchol in two oral suspension strengths, 1.875 grams per packet and 3.75...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.